FP7-HEALTH 602570 - iHIVARNA: TriMix-mRNA candidate vaccine for treatment of patients with chronic HIV-1 infection receiving antiretroviral treatment

FP7-HEALTH 602570 - iHIVARNA: TriMix-mRNA candidate vaccine for treatment of patients with chronic HIV-1 infection receiving antiretroviral treatment

01/12/2013

Finding an alternative to antiretroviral therapy for life is a hot topic in the field of HIV research, with therapeutic vaccination currently appearing to be the best option. iHIVARNA aims to successfully vaccinate HIV-infected patients receiving antiretroviral treatment with three injections of the HIV-TriMix-mRNA therapeutic candidate vaccine, with the aim of improving the efficacy of therapeutic vaccination against HIV infection. The ultimate goal of the project is to generate knowledge aimed at achieving functional cure of HIV-infected patients.

  • Participant entities: IrsiCaixa AIDS Research Institute, Vrije Universiteit Brussel, Erasmus Universitair Medisch Centrum Rotterdam, Asphalion, Etherna, Synapse Research Management Partners, Prins Leopold Instituut Voor Tropische Geneeskunde
  • Strategic line: Microbiome, Prevention, eradication and functional cure
  • Funding entity: Comisión Europea. FP7-HEALTH

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Member of:

Cerca

In cooperation with: